aTYR PHARMA INC (ATYR) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-28

aTYR PHARMA INC (ATYR) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-28. 4 Form 8-K material event filings were reported by ATYR in the last 90 days. InsiderAlpha tracks every ATYR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About aTYR PHARMA INC (ATYR)

SIC classification	Biological Products, (No Diagnostic Substances) (SIC 2836)
SEC CIK	0001339970

90-Day SEC Filing Activity

Form 4 filings (90d)	7
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-05-28

Recent ATYR Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-27	SCHIMMEL PAUL	Insider	P — Open-market purchase	100.0K	$0.50	$50K	SEC
2026-02-04	DENYES NANCY	General Counsel	S — Open-market sale	1.1K	$0.98	$1K	SEC
2026-02-04	Broadfoot Jill Marie	Chief Financial Officer	S — Open-market sale	1.6K	$0.98	$2K	SEC
2026-02-04	Shukla Sanjay	President and CEO	S — Open-market sale	3.7K	$0.98	$4K	SEC
2026-02-03	Broadfoot Jill Marie	Chief Financial Officer	M — Option exercise	3.8K	—	—	SEC
2026-02-03	Shukla Sanjay	President and CEO	M — Option exercise	10.4K	—	—	SEC
2026-02-03	DENYES NANCY	General Counsel	M — Option exercise	2.7K	—	—	SEC
2025-10-09	SCHIMMEL PAUL	Insider	P — Open-market purchase	318.0K	$0.94	$299K	SEC
2025-10-08	SCHIMMEL PAUL	Insider	P — Open-market purchase	682.0K	$0.90	$612K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for aTYR PHARMA INC (ATYR). Updated in real time as new filings are submitted to the SEC.

Most-Active ATYR Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
SCHIMMEL PAUL	2	$50K
Lucas Svetlana	1	—
BENEVICH ERIC	1	—
Coughlin Timothy	1	—
Gross Jane A	1	—

Recent ATYR Form 8-K Material Events

2026-06-08 — Item 3.01 [SEC]
2026-06-01 — Item 7.01, 9.01 [SEC]
2026-05-15 — Item 2.02, 9.01 [SEC]
2026-05-11 — Item 2.02, 7.01, 8.01, 9.01 [SEC]
2026-03-05 — Item 2.02, 9.01 · Earnings · neutral [SEC]
aTyr Pharma issued a press release on March 5, 2026 announcing financial results for the year ended December 31, 2025. The filing provides standard annual financial results without explicit beat/miss language or forward guidance changes.

Recent Insider Filings

2026-05-28 — SCHIMMEL PAUL (Insider)
2026-05-13 — Coughlin Timothy (Insider)
2026-05-13 — BENEVICH ERIC (Insider)
2026-05-13 — Gross Jane A (Insider)
2026-05-13 — Lucas Svetlana (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ATYR insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ATYR Insider Trading — FAQ

What is the latest insider trade for ATYR?: aTYR PHARMA INC (ATYR) had 7 insider filings in the last 90 days, with the most recent on 2026-05-28. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ATYR stock?: 0 insider purchases of ATYR were filed in the last 90 days.
How many insiders are selling ATYR stock?: 0 insider sales of ATYR were filed in the last 90 days.
Where can I see ATYR SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ATYR SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live ATYR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.